Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2010-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/era.10.115PMID 20836682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo

  2011cited by this paper
• Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02.

  2010cited by this paper
• Tobacco Use in Human Papillomavirus–Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence

  2010cited by this paper
• Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

  2010cited by this paper
• Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.

  2010cited by this paper
• Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer

  2010cited by this paper
• HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance.

  2010cited by this paper
• An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).

  2010cited by this paper
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

  2010cited by this paper
• Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

  2010cited by this paper
• Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1

  2010cited by this paper
• Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death

  2009cited by this paper
• Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC).

  2009cited by this paper
• Clinical significance of type 1 insulin-like growth factor receptor and insulin-like growth factor binding protein-3 expression in squamous cell carcinoma of head and neck.

  2009cited by this paper
• Genetic Signatures of HPV-related and Unrelated Oropharyngeal Carcinoma and Their Prognostic Implications

  2009cited by this paper
• Treating IIA/B seminoma with combination carboplatin and radiotherapy.

  2009cited by this paper
• Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

  2009cited by this paper
• Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  2009cited by this paper
• HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

  2009cited by this paper
• BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy

  2009cited by this paper
• Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab

  2009cited by this paper
• Defining Molecular Phenotypes of Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma

  2009cited by this paper
• A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG).

  2009cited by this paper
• Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck

  2009cited by this paper
• Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129.

  2009cited by this paper
• Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

  2009cited by this paper
• The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck.

  2009cited by this paper
• Squamous cell carcinoma of base of tongue in a patient with Fanconi's anemia treated with radiation therapy: Case report and review of literature

  2009cited by this paper
• Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

  2009cited by this paper
• Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications

  2008cited by this paper
• Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma

  2008cited by this paper
• Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.

  2008cited by this paper
• Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.

  2008cited by this paper
• Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

  2008cited by this paper
• Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas.

  2008cited by this paper
• Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms

  2008cited by this paper
• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

  2008cited by this paper
• Combined Inhibition of cSrc and Epidermal Growth Factor ReceptorAbrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma

  2008cited by this paper
• Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.

  2008cited by this paper
• Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2

  2007cited by this paper
• Prognostic impact of HER‐2/neu expression on squamous head and neck carcinomas

  2007cited by this paper
• A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells

  2007cited by this paper
• Alcohol Metabolism and Cancer Risk

  2007cited by this paper
• Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: Roles of E6 and E7 proteins

  2007cited by this paper
• Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer

  2007cited by this paper
• Identification of a novel EGF-sensitive cell cycle checkpoint.

  2007cited by this paper
• Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

  2007cited by this paper
• Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma

  2007cited by this paper
• Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

  2007cited by this paper
• Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator.

  2007cited by this paper
• Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysis

  2007cited by this paper
• Genetic polymorphisms in DNA base‐excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck

  2007cited by this paper
• Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells

  2007cited by this paper
• Mechanisms for oncogenic activation of the epidermal growth factor receptor.

  2007cited by this paper
• BASIC SCIENCE REVIEW

  2007cited by this paper
• Hypoxia induces transforming growth factor-beta1 gene expression in the pulmonary artery of rats via hypoxia-inducible factor-1alpha.

  2007cited by this paper
• Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

  2007cited by this paper
• BASIC SCIENCE REVIEW

  2007cited by this paper
• The mechanics of base excision repair, and its relationship to aging and disease.

  2007cited by this paper
• Hypoxia Induces Transforming Growth Factor-β1 Gene Expression in the Pulmonary Artery of Rats via Hypoxia-inducible Factor-1α

  2007cited by this paper
• Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

  2006cited by this paper
• Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  2006cited by this paper
• Epidermal growth factor receptor biology in head and neck cancer.

  2006cited by this paper
• Epidermal growth factor receptor (EGFR) signaling in cancer.

  2006cited by this paper
• Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell Carcinoma

  2006cited by this paper
• Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

  2006cited by this paper
• Co‐regulation of B‐Myb expression by E2F1 and EGF receptor

  2006cited by this paper
• Related citationsHypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells.

  2006cited by this paper
• The Ras/Raf/MAPK pathway.

  2006cited by this paper
• Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

  2006cited by this paper
• Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

  2006cited by this paper
• A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

  2006cited by this paper
• A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer

  2006cited by this paper
• A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial

  2006cited by this paper
• Clinical implications of human papillomavirus in head and neck cancers.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

  2006cited by this paper
• Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.

  2005cited by this paper
• Prognostic Significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

  2005cited by this paper
• Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

  2005cited by this paper
• Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden

  2005cited by this paper
• Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity.

  2005cited by this paper
• Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas.

  2005cited by this paper
• Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.

  2005cited by this paper
• Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

  2005cited by this paper
• Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor against Head and Neck Squamous Cell Carcinoma In vitro and In vivo

  2005cited by this paper
• Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.

  2005cited by this paper
• Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase*

  2005cited by this paper
• The development of proteasome inhibitors as anticancer drugs.

  2004cited by this paper
• Focus on head and neck cancer.

  2004cited by this paper
• Insulin-like growth factors and neoplasia

  2004cited by this paper

• Biological and Molecular Biomarkers in Oral Potentially Malignant Disorders and Oral Cavity Squamous Cell Carcinoma—Innovation and Insights

  2025cites this paper
• Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma

  2022cites this paper
• Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck

  2021cites this paper
• Head and neck cancer and non‐steroidal anti‐inflammatory drugs: Systematic review and meta‐analysis

  2021cites this paper
• A 8-gene-methylation-based Signature for Head and Neck Squamous Cell Carcinoma Prognosis

  2021cites this paper
• Expression of Cyclin-D1 and p53 as Prognostic Markers in Treatment of Oral Squamous Cell Carcinoma

  2021cites this paper
• Prognostic Implications of EGFR, p53, p16, Cyclin D1, and Bcl‐2 in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2020cites this paper
• Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.

  2020cites this paper
• RCOR1 directly binds to MED28 and weakens its inducing effect on cancer stem cell-like activity of oral cavity squamous cell carcinoma cells.

  2020cites this paper
• Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas

  2019cites this paper
• Prognostic Significance of Cyclins A2, B1, D1, and E1 and CCND1 Numerical Aberrations in Oral Squamous Cell Carcinomas

  2018cites this paper
• Long non-coding RNA gastric carcinoma highly expressed transcript 1 promotes cell proliferation and invasion in human head and neck cancer

  2018cites this paper
• An immunohistochemical score to predict the outcome for oral squamous cell carcinoma

  2018cites this paper
• Prognostic significance of CD44v6, p63, podoplanin and MMP-9 in oral squamous cell carcinomas.

  2016cites this paper
• Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review

  2016cites this paper
• Thyroid Cancer Metabolism: A Review

  2016cites this paper
• Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck

  2015cites this paper
• Bioanalytical methods for metabolomic profiling: Detection of head and neck cancer, including oral cancer

  2015cites this paper
• Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas.

  2014cites this paper
• Autophagy Interplays with Apoptosis and Cell Cycle Regulation in the Growth Inhibiting Effect of Trisenox in HEP-2, a Laryngeal Squamous Cancer

  2014cites this paper
• C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival.

  2013cites this paper
• Expression of EPHRIN-A 1 , SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD 8 + T cells

  2013cites this paper
• Cancer metabolism, stemness and tumor recurrence

  2013cites this paper
• MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer

  2013cites this paper
• Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells

  2013cites this paper
• Role of Met Axis in Head and Neck Cancer

  2013cites this paper
• Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma.

  2013cites this paper
• Combined cytoplasmic and membranous EGFR and p53 overexpression is a poor prognostic marker in early stage oral squamous cell carcinoma.

  2012cites this paper
• Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target.

  2012cites this paper
• Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer

  2012cites this paper
• CANCER BIOMARKER DISCOVERY BY IN VITRO SYSTEMS BIOLOGY

  2011cites this paper
• Regulatory roles of calprotectin in head and neck squamous cell carcinogenesis.

  2011cites this paper
• Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues.

  2011cites this paper